The system features Synchrony cochlear implant that stimulates the auditory nerve for high-frequency hearing loss, as well as Sonnet EAS audio processor with built-in acoustic amplification for low-frequency hearing loss.
The EAS System has secured approval for people aged 18 years and older who have normal to moderate sensorineural hearing loss in the low frequencies, sloping to a severe-to-profound hearing loss in the high frequencies.
MED-EL said that around 97% of patients participating in its clinical trial reported a benefit from EAS within the first 12 months.
MED-EL North America CEO and president Raymond Gamble said: “The EAS System has the potential to close the gap for people who have high-frequency hearing loss, but whose residual low-frequency hearing would have made them ineligible for a cochlear implant up until now.
“If you struggle with hearing in background noise with hearing aids, you may be a candidate for the EAS System.”
With 29 subsidiaries across the globe, Austria-based MED-EL Medical Electronics supplies hearing implant systems.
The firm offers a range of implantable solutions to treat various degrees of hearing loss, including cochlear and middle ear implant systems.
In July this year, MED-EL acquired a novel non-surgical bone conduction system from the Swedish medical device company Otorix.
Image: MED-EL Synchrony electric acoustic stimulation hearing implant system. Photo: courtesy of Business Wire.
